Health Vidya

Based on a review of this drug by the National Academy of Sciences-National Research and/or other information, the FDA has classified the indications as follows: For the relief of symptoms associated with cerebrovascular insufficiency. In peripheral vascular disease of arteriosclerosis obliterans, thromboangitis obliterans (Buerger's disease) and Raynaud's disease. Final classification of the less-than-effective indications requires further investigation.